Trends in Utilization of Guideline-Directed Cardiorenal Protective Therapies for Chronic Kidney Disease in Patients with Cardiovascular Morbidity: Real World Data from Two Cross-Sectional Snapshots (HECMOS I and II)

<b>Introduction:</b> Chronic kidney disease (CKD) affects roughly 10% of the global population and significantly increases cardiovascular risk. While renin–angiotensin system inhibitors (RASi) remain a therapeutic mainstay, recent evidence supports the renoprotective value of sodium–glucose cotransp...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Panagiotis Theofilis, Ioannis Leontsinis, Dimitrios Farmakis, Dimitrios Avramidis, Nikolaos Argyriou, Matthaios Didagelos, Ioannis Zarifis, Costas Thomopoulos, Anastasia Kitsiou, Georgios Koutsopoulos, George Kourgianidis, Athanasios Kostopoulos, Eleni Manta, Maria Marketou, Vasiliki Bistola, George Bibis, Katerina K. Naka, Periklis Ntavlouros, Evangelos Oikonomou, Sotirios Patsilinakos, Nikolaos Patsourakos, Asaf Sawafta, Vaios Schismenos, Athanasios Trikas, Georgios Chalikias, Christos Chatzieleftheriou, Konstantinos Tsioufis
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2025-08-01
Rangatū:	Biomedicines
Ngā marau:	chronic kidney disease finerenone heart failure SGLT2 inhibitor
Urunga tuihono:	https://www.mdpi.com/2227-9059/13/8/1987
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!